Open-Label Extension Trial to Characterize the Long-term Safety and Tolerability of Elamipretide in Subjects With Genetically Confirmed Primary Mitochondrial Myopathy (PMM)



Status:Enrolling by invitation
Healthy:No
Age Range:16 - Any
Updated:4/17/2018
Start Date:December 2016
End Date:December 2021

Use our guide to learn which trials are right for you!

A Multicenter, Open-Label Phase 2 Extension Trial to Characterize the Long-term Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Genetically Confirmed Primary Mitochondrial Myopathy (PMM)

This is a Phase 2 Open-Label extension study to evaluate the long term safety and
tolerability of daily elamipretide injections in patients with genetically confirmed Primary
Mitochondrial Disease who previously participated in the SPIMM-202 Clinical Trial

This open-label, non-comparative, extension trial will enroll subjects with genetically
confirmed PMD who have completed the End-of-Study Visit in the SPIMM-202 trial. Subjects who
do not discontinue or withdraw from the trial will receive treatment with 40 mg SC
elamipretide for the shortest of the following: 260 weeks; regulatory approval and commercial
availability of elamipretide in the subject's respective country; or termination of the
clinical development for elamipretide in subjects with PMD.

Inclusion Criteria:

- Investigator determines the subject can, and subject agrees to, adhere to the trial
requirements for the length of the trial including self-administration (by subject or
trained caregiver) of the study drug

- Subject completed the End-of-Study Visit in SPIMM-202

Exclusion Criteria:

- Subject has any prior or current medical condition that, in the judgment of the
Investigator, would prevent the subject from safely participating in and/or completing
all trial requirements

- Subject has received any investigational compound (excluding elamipretide) and/or has
participated in another interventional clinical trial within 30 days prior to the
SPIMM-203 Baseline Visit (excluding SPIMM-202) or is concurrently enrolled in any
non-interventional research of any type judged to be scientifically or medically
incompatible with the trial as deemed by the Investigator in consultation with the
Sponsor

- Subject experienced an adverse reaction attributed to study drug resulting in
permanent discontinuation of study drug in the SPIMM-202 trial.

- Female subjects who are pregnant, planning to become pregnant, or lactating

- Subject has undergone an in-patient hospitalization within the 1 month prior to the
SPIMM-203 Baseline Visit
We found this trial at
4
sites
4401 Penn Avenue
Pittsburgh, Pennsylvania 15224
412-692-5325
Children's Hospital of Pittsburgh of UPMC UPMC is one of the leading nonprofit health systems...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
1 Perkins Square
Akron, Ohio 44308
(330) 543-1000
Akron Children's Hospital From humble beginnings as a day nursery in 1890, Akron Children
?
mi
from
Akron, OH
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
?
mi
from
Boston, MA
Click here to add this to my saved trials
San Diego, California 92103
?
mi
from
San Diego, CA
Click here to add this to my saved trials